Effects of Ramelteon (8mg) Alone and in Combination With Multi-Component Behavioral Therapy on Sleep and Circadian Phase in Patients With Chronic Insomnia (CBT)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by University of Arizona.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
University of Colorado, Denver
Information provided by:
University of Arizona
ClinicalTrials.gov Identifier:
NCT01180855
First received: August 9, 2010
Last updated: August 11, 2010
Last verified: August 2010
  Purpose

The specific aims of the proposed study are to compare the sleep, daytime functioning, and circadian phase effects of ROZEREMTM (ramelteon/TAK-375) a selective MT1/MT2 melatonin receptor agonist in humans alone and in combination with multi-component behavior therapy (MCBT) in patients with chronic insomnia.


Condition Intervention Phase
Insomnia
Drug: Placebo
Drug: Rozerem 8mg
Other: Rozerem 8mg in combination with Multi Component Behavior Therapy
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Ramelteon (8mg) Alone and in Combination With Multi-Component Behavioral Therapy on Sleep and Circadian Phase in Patients With Chronic Insomnia: A Randomized, Double-Blind, Placebo Controlled Study (Investigator Initiated Study)

Resource links provided by NLM:


Further study details as provided by University of Arizona:

Primary Outcome Measures:
  • Sleep Onset Latency [ Time Frame: Baseline, Post treatment, 3 month follow up ] [ Designated as safety issue: No ]
    Daily assessment of sleep and daytime functioning (daily voice mail sleep diary and actigraphy) for 10 weeks: 2 weeks prior to and after treatment and during the 6 week treatment period. The primary sleep outcomes will be improvement in sleep onset latency (SOL) and total sleep time (TST).


Secondary Outcome Measures:
  • Dim Light Melatonin Onset [ Time Frame: Baseline, post treatment ] [ Designated as safety issue: No ]
    Assessment of circadian melatonin phase 2 weeks prior to and 2 weeks after treatment(dim light melatonin onset—DLMO, 2 weeks prior to treatment and 2 weeks post treatment assessment of quality of life (SF-36) and sleep quality (Pittsburgh Sleep Quality Index—PSQI), 2 weeks prior to treatment and 2 weeks post treatmemnt daily assessment of daytime functioning.


Enrollment: 30
Study Start Date: August 2007
Estimated Study Completion Date: September 2010
Estimated Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo pills prepared by Takeda Pharmaceutical.
Drug: Placebo
Placebo pill nightly for 42 nights.
Active Comparator: Rozerem
Rozerem 8mg
Drug: Rozerem 8mg
Rozerem 8mg pill, nightly for 42 nights
Active Comparator: Rozerem + Multi Component Behavior Therapy
Rozerem 8mg in combination with 4 small group sessions and 2 phone calls of Multi Component Behavior Therapy.
Other: Rozerem 8mg in combination with Multi Component Behavior Therapy
Rozerem 8mg pill nightly for 42 nights with 4 sessions and 2 telephone calls of Multi Component Behavior Therapy.

  Eligibility

Ages Eligible for Study:   18 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Medical and sleep/wake history. During the screening process, participants will receive a physical exam, urine and blood labs, and be interviewed about their medical and sleep/wake history and be asked questions about their present and past habitual sleep/wake schedule and nap times.

    (b) Medication/drug/alcohol use. Participants must have no history of drug or alcohol abuse or dependency, consume no more than 2 alcoholic beverages a day or more than 14 per week, Participants must agree not to consume more than 2 beverages containing caffeine (caffeinated coffee, tea, colas) a day before 2 pm and none after 2 pm.

    (c) Evaluation of Psychiatric/Psychological Suitability. Participants must demonstrate a full understanding of the requirements and demands of the study.

For inclusion/exclusion screening, participants will receive a sleep, medical, physical and psychiatric history examination, one-night of dim light melatonin onset evaluation in the sleep laboratory, one-night of polysomnography, and two weeks of baseline sleep assessment. If during the polysomnography assessment the participant had a respiratory disturbance index (RDI) of 15 or more, the participant would be considered to have met the exclusionary criterion for obstructive sleep apnea. A letter providing feedback of the all night polysomnography assessment will be sent to all participants.

Individuals with a history of psychiatric illnesses or psychiatric disorders will be excluded, such as but not limited to, alcoholism, drug dependency, mood disorders; schizophrenic disorders, anxiety disorders; personality disorders. Finally, individuals who are unaware of specific psychiatric diagnoses who have a history of having been treated with antidepressants, neuroleptic medications or major tranquilizers will be excluded from study. However, a personal history of limited prior counseling or psychotherapy (e.g., for adjustment reactions) will not be exclusionary. Individuals who have been treated for insomnia within the past six months will be excluded.

Exclusion Criteria:

  • Exclusion criteria include diagnosis or treatment of other sleep disorders such as obstructive sleep apnea, narcolepsy, sleep walking, and periodic limb movement disorders. Participants with a history of night work in the preceding 6 months or transmeridian travel (across >3 time zones) in the last 1 month prior to the study will be excluded.

Use of psychotropic, hypnotic medications known to affect sleep or contraindicated for use with ramelteon, or over-the-counter analgesics that contain caffeine, or herbal supplements, including products with herbs, melatonin, or St. John's Wort.

Substance use will be determined by self-report and urine toxicology during the screening visit. Women who are pregnant or are planning on becoming pregnant will be excluded from the study. Female participants will be given a pregnancy test during the screening process.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01180855

Locations
United States, Arizona
University of Arizona Sleep Research Laboratory
Tucson, Arizona, United States, 85721
Sponsors and Collaborators
University of Arizona
University of Colorado, Denver
Investigators
Principal Investigator: Richard R Bootzin, PhD University of Arizona
  More Information

No publications provided

Responsible Party: Richard R. Bootzin, PhD Professor of Psychology, University of Arizona
ClinicalTrials.gov Identifier: NCT01180855     History of Changes
Other Study ID Numbers: 06-046R
Study First Received: August 9, 2010
Last Updated: August 11, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by University of Arizona:
Melatonin
Cognitive Behavior Therapy

ClinicalTrials.gov processed this record on September 18, 2014